PubMed Health⌕ Search

Biomedical subjects

V Koza

Publications and source records attributed to V Koza.

47 records · Page 3Linked to original sources
PubMed1990

Cleaved and multilobated cell immunocytoma of low grade malignancy with amyloid. An immunohistochemical and electron microscopical study.

An unusual variant of immunocytoma of low grade malignancy, cytologically resembling follicular cleaved-cell malignant lymphoma is described. Presence of heavy deposits of amyloid, intracytoplasmic monoclonal IgM-kappa immunoglobulin, cells with Dutcher inclusions, electron-microscopic features and negativity of T-cell markers led to diagnosis of immunocytoma. After cytostatic chemotherapy the lymphoma changed its morphology into typical lymphoplasmacytoid immunocytoma.

Aged↗
PubMed1990

[Changes in hemostasis in blood donors on the Fenwal CS 3000 separator].

During thrombocytophereses on a blood cell FENWAL CS 3000 separator in one group of donors the anticoagulant solution ACD-A recommended by the manufacturer was used, in the other group of donors ACD-A with heparin was used. The authors give an account of the changes in some parameters of haemostasis in these donors on the separator incl. examination of fibrinopeptide A which is the most sensitive indicator of clotting activity during separation. Heparin administration prevented a rise of fibrinopeptide A and did not lead to a reduced platelet yield.

Adult↗
PubMed1990

[Treatment of myelodysplastic syndrome using continual subcutaneous infusion of low doses of cytosine arabinoside].

The authors summarize their experience with the administration of small doses of cytosine arabinoside continuously by subcutaneous infusion in 13 patients with myelodysplastic syndrome. Alcysten Spofa was administered in doses of 20 mg/sq.m per day for 5-17 days in one cycle. A total of 26 therapeutic cycles were administered. Favourable responses were obtained in four patients, partial results were achieved in two patients; in seven instances treatment produced no response. The authors compare also the results obtained in this group with a previous group of 11 patients treated with small doses of cytosine arabinoside, which was administered intermittently, i.e. twice a day by the subcutaneous route. Continuous administration did not produce more favourable therapeutic results, it caused however a larger number of infections and haemorrhagic complications as compared with intermittent administration. The authors recommend administration of small doses of cytosine arabinoside in patients with prognostically adverse types of myelodysplastic syndrome - intermittently 10 mg subcutaneously twice a day for 14-21 days.

Aged↗
PubMed1989

[Intensive post-remission therapy of acute myeloid leukemia with high doses of cytosine arabinoside].

The results are estimated of treatment for acute myeloid leukaemia using intensive post-remission therapy with high doses of cytosine arabinoside (HiDAC). Two women and four men aged 18-34 years were treated with HiDAC. None of them had been given maintenance or boost chemotherapy any more at the time. The patients were rated for the duration of granulocytopenia and thrombocytopenia for the incidence of non-haematological complications and for the duration and quality of survival. The preliminary results are promising and in keeping with those reported by similar clinical centres abroad, namely that maintenance therapy should be phased out in the presence of intensive post-remission treatment.

Adolescent↗
PubMed1989

[Treatment of medium and highly malignant non-Hodgkin's lymphoma with combined chemotherapy using methotrexate, adriamycin, cyclophosphamide, vincristine, prednisone and bleomycin (protocol MACOP-B)].

Combined chemotherapy, protocol MACOP-B, was administered to 21 patients with non-Hodgkin lymphoma (NHL) with a medium or high grade of malignity, clinical stage II-IV. Complete remission was achieved in 17 patients (81%), in one instance partial remission was induced. One patient died from a cardiovascular and one from a thromboembolic complication during treatment. In one patient the results were not evaluated. Three patients developed severe granulocytopenia which called for reduction or delay of treatment and a septic condition developed. In addition to myelosuppression the main complications were stomatitis and mycosis. No death caused by infectious or haemorrhagic complications was recorded. The described chemotherapy is recommended in particular in immunoblastic lymphomas, diffuse lymphomas from cleaved and non-cleaved cells and diffuse lymphomas with mixed cellularity.

Adult↗
PubMed1989

[Locally produced monoclonal antibodies for the diagnosis of acute leukemias].

In 35 cases of acute leukaemia in addition to the basic morphological and cytochemical examination immunophenotyping with locally produced monoclonal antibodies from the Institute of Molecular Genetics, Czechoslovak Academy of Sciences, Prague, was made. In 33 instances it proved possible to differentiate the leukaemic cells, two leukaemias were described as non-differentiated. Local antibodies MEM 78, MEM 75, MEM 57, MEM 32, MEM 31, MEM 18 and HL-40 can be considered basic monoclonal antibodies for the diagnosis of acute leukaemia.

Acute Disease↗
PubMed1989

[Immunoenzyme phenotyping of cells of domestically-produced monoclonal antibodies on dried smears of peripheral blood and bone marrow].

The authors describe the indirect immunoperoxidase method which makes possible immunophenotyping of cells on dried smears of peripheral and bone marrow. They used only local currently available monoclonal antibodies with a diagnostic value in lymphoproliferative conditions. The above procedure makes it possible to examine stored non-fixed smears, to evaluate the morphology of positive and negative cells and to evaluate findings retrospectively.

Antibodies, Monoclonal↗
PubMedDate not supplied

[Central venous sepsis in long-term catheterization of patients during intensive treatment of acute leukemia].

The authors evaluate the prevalence of central venous catheter sepsis and possible catheter sepsis in granulocytopenic patients with acute leukaemia after intensive treatment with cytostatics. The group comprises 42 patients subjected to 57 catheterizations of a central vein. The period of catheterizations was 18-89 days, the average period 43 days. Catheter sepsis was revealed in 15 patients, i.e. 26.3% of all performed catheterizations, possible catheter sepsis was recorded in four patients, i. e. 7.0%. In almost half of the catheter sepses (42.1%) the same microbiological finding was recorded in the haemoculture and skin smear at the site of insertion of the catheter. Twelve patients were cured (21.0%), seven patients (16.7%) from the group of 42 died. To reduce the incidence of catheter sepsis it is important in the authors' opinion to make available high quality protective materials (Tegaderm plasters) and the entire infusion line should be changed daily.

Acute Disease↗